Uber obtains license for imported drug with anti-epileptic drug Vimpat

recently, the BelgianPharmaceutical(http://giant UCB announced that thecompany(http://has obtained an imported drug license (IDL) of the anti-epileptic drugfrom The nationaldrug(http:// regulatory agency (NMPA), which will enable Vimpat to be listed in China for treatment of epilepsy patientsVimpat's indications in China are: as an auxiliary treatmentdrug(http://for the treatment of partial seizures (accompanied or not secondary systemic seizures) in adolescents and adults aged 16 and overabout Vimpat
Vimpat is a new type of NMDA receptor glycine site binding antagonist, belonging to a new class of functional amino acids, is a new dual mechanism of anticonvulsant drugscompared with other anti-epileptic drugs, Vimpat has the activity of regulating sodium ion channels, sodium ion channels in regulating nervous system activity, promoting the conduction between nerve cells has a very important function, by reducing the hyperactivity of sodium ion channels can control the activity of nerve cells to treat epilepsy in the European Union, Vimpat was first approved as an auxiliary drug for the treatment of partial seizure seclampsia (accompanied or not accompanied by secondary full-blown seizure seclampsia) in children 4 years and older, adolescents and adults in eu countries, Vimpat has a film coat, syrup, and injections Vimpat injections are another alternative form of dosage in patients who are temporarily unable to administer orally in Asia, Vimpat tablets, oral solutions, and intravenous fluids are available in Korea, Hong Kong, Malaysia, the Philippines, Thailand and Japan